Prof Wyllie, Director and Founder of Global Pharma Consulting, is a graduate of the University of Aberdeen. He has over 30 years of experience in senior management positions in the pharmaceutical industry. While Director at Pfizer he was involved in the discovery, filing of intellectual property, development, regulatory filing and marketing of eight major pharmaceutical products including, amlodipine (Norvasc), doxazosin (Cardura), darifenacin (Enablex), fluconazole (Diflucan) sertaline (Zoloft) and sildenafil (Viagra). Subsequently, he has been involved in founding and successfully funding several ‘start up’ companies and the listing of four of these on the London Stock Market.
He is founder and CSO of Plethora Solutions Plc (AIM:PLE) which has a product, PSD502, undergoing regulatory review in the EU for premature ejaculation and which has been out-licensed to a major pharmaceutical company. He is Chairman of Glycomar Ltd, the Oban-based marine biotechnology company and a non- executive director of Repros Therapeutics (NASDAQ:RPRX) and Xion Inc. He is a founder member of both the International Advisory Board and Commercial Advisory Panel for Strathclyde University in Glasgow.